Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Mehta Analysis: Race To Harness Data Will Revolutionize PBM System

Data and intelligence will drive revolutionary changes in healthcare, and today's power brokers will need to adapt. Viren Mehta, founding partner of Mehta Partners LLC, considers how business consolidation in the complex US pharma market reflects the race to tap as yet under-exploited data troves, and how the resulting exploitation of those data may benefit a broader set of stakeholders.

Pharmacy Benefit Management Commercial United States
Advertisement

Strategy

Set Alert for Strategy

Latest From Strategy

While The Money Flows, So Will Biopharma IPOs

US initial public offerings by biopharma firms in 2017 have outpaced the number of IPOs completed in the previous year and as investors continue to see big returns the pace isn't likely to slow in 2018.

Financing Business Strategies

Piramal Pharma Solutions CEO On Building ‘Symbiotic’ Preferred Partnerships

The Indian contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS) expects to grow its pool of “preferred partnerships” that includes a mix of both biotechs and large pharma. In an interview with Scrip, CEO Vivek Sharma outlined the value of such “symbiotic” relationships and how PPS is focused on quality as a culture rather than purely limiting it to inspection clearance and product approvals.

Commercial Strategy

PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.

Market Intelligence ImmunoOncology

Gates Injects UK-US Dementia Discovery Fund With $50m And Fresh Purpose

The Dementia Discovery Fund won a $50m private investment from Bill Gates – plus his ringing support to probe beyond the amyloid beta hypothesis in hopes of eventually defeating Alzheimer's.

Financing Innovation

BeiGene Unveils New Cancer Drug Plant With Eye On Affordability

A pure drug developer just a year ago, BeiGene has transformed itself into a full-fledged drug maker with its own R&D, manufacturing and commercial operations. But the Nasdaq-listed biotech is looking well beyond speed, including towards a thrust on quality, as it unveils a production site in Suzhou.

Commercial Strategy

Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

Generic Drugs Strategy
See All
UsernamePublicRestriction

Register